Medical Xpress July 26, 2024
New research from the Center for Integration of Science and Industry at Bentley University shows that differences between the financial structures of large pharmaceutical producers and smaller, emerging biotechnology companies creates synergies that contribute to the pipeline of new, innovative products in response to reductions in drug prices anticipated under the Inflation Reduction Act (IRA).
While large pharmaceutical producers would likely reduce R&D spending in response to lower product revenues, R&D in smaller biotechnology companies is not likely to decrease and could sustain both corporate profits and new product approvals at current levels.
This analysis suggests claims that the IRA would reduce the number of new drugs for unmet medical needs are likely false.
A paper titled “Modeling impact of...
Today's Sponsors
Today's Sponsor